ClinicalTrials.gg
TerminatedNCT00604968Updated Jun 7, 2017Results posted

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

A Phase 4 interventional study of Caelyx (pegylated liposomal doxorubicin; SCH 200746) in Breast Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Feb 2007, registered Jan 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
55th of 66
25 · median 57
Started
2007
with 6 others
Phase 4
6 of 67
none open now
Registered
25th of 67
by date
Lead sponsor
5 of 67
Merck Sharp & Dohme LLC

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 55th largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2007, is one of 6 in phase 4, and was the 25th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of pegylated liposomal doxorubicin (Caelyx) in elderly patients who are to receive first-line chemotherapy for metastatic or locally advanced breast cancer, not amenable to surgery.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients meeting the following criteria will be eligible for enrollment.

    • Female patients with histologic or cytologic diagnosis of breast cancer that is locally advanced or , and not amenable to surgery.
    • Age >= 65 years.
    • World Health Organization (WHO) Performance Status 0 - 2
    • in accordance with (RECIST) criteria. Patients with bone metastasis can also be included but will be evaluated according to WHO criteria. Patients with non-measurable disease can also be included.
    • (LVEF) >= 50% verified by ultrasound cardiography (UCG); no clinical signs of heart disease.
    • Normal organ function, except due to disease involvement, however maximum deviation:

      • S-creatinine \<= 1.5 x upper normal limit;
      • \<= 2 x upper normal limit;
      • (ALAT) and/or aspartate aminotransferase (ASAT) \<= 3 x upper normal limit. In case of liver metastases, ALAT and/or ASAT \<= 5 x upper normal limit.
    • Adequate bone marrow function, ie:

      • >= 100 x 10\^9/L;
      • Neutrophils >= 1.5 x 10\^9/L;
      • White Blood Cell (WBC) >= 3.0 x 10\^9/L;
      • > 90 g/L.
    • >= 12 weeks.
    • Patients having received oral and written information and having provided written .

Exclusion criteria

Exclusion Criteria:

  • Patients will not be enrolled if any of the following conditions apply.

    • Previous chemotherapy for disease. (The patient may have received previous endocrine therapy or single-drug Herceptin. Intrapleural or intrapericardial Novantrone is allowed.)
    • Recurrence \<= 12 months after anthracycline-containing treatment and/or prior doxorubicin > 300 mg/m\^2 or epirubicin > 540 mg/m\^2.
    • Myocardial infarction within 6 months of planned inclusion.
    • Symptomatic .
    • Human Epidermal growth factor Receptor 2 () positivity eligible for treatment with trastuzumab, or estrogen receptor (ER) positivity eligible for hormonal therapy.
    • Allergy to anthracyclines.
    • Uncontrolled infection.
    • Other not radically treated .
    • Other disease or condition contraindicating treatment or not allowing follow-up.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Caelyx

    Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)

Interventions

  • Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).

06

What researchers measure

Primary outcomes

  1. Time to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death).

    Treatment failure was defined as progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death. Progressive Disease according to RECIST response criteria: \>=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease. Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.

    Time frame: Time of treatment until progression of disease or unacceptable toxicity leading to discontinuation of treatment or death, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

Secondary outcomes

  1. Number of Patients With Stable Disease (SD) as Best Response

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST response criteria for SD required steady state of response of at least 9 weeks duration. There may be no appearance of new lesions. WHO response criteria for SD required no significant change for at least 8 weeks.

    Time frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  2. Number of Patients With Partial Response (PR) as Best Response

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST PR criteria required \>=30% decrease in certain target lesions \& no increase in size of non-target lesions or appearance of new lesions WHO PR criteria required partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for \>=4 wks

    Time frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  3. Number of Patients With Progressive Disease (PD) as Best Response

    Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST PD criteria required \>=20% increase in certain target lesions OR progression of non-target lesions, or appearance of new lesions WHO PD criteria required increase in size of existing lesions or appearance of new lesions.

    Time frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  4. Number of Patients Requiring Dose Reduction

    The protocol contains instructions to reduce the Caelyx dose according to specific schedules, in cases necessary due to reasons such as hematological toxicity, non-hematological toxicity, cardiotoxicity, or other toxic side-effects of treatment reducing quality of life etc.

    Time frame: Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment).

  5. Time to Response

    Response can be partial (\>=30% decrease in the sum of Longest Diameter of target lesions, determined by two observations not less than 4 weeks apart; no unequivocal increase in the size of non-target lesions or the appearance of new lesions may occur) or complete (disappearance of all clinical evidence of tumor determined by 2 observations not less than 4 weeks apart), whichever status is recorded first.

    Time frame: Time of treatment until response, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  6. Duration of Response

    Duration of response is defined as the time span from the first evaluation that shows response until the first evaluation that shows progression. Where patients did not show progress, duration of response was measured from the first evaluation that showed response until they discontinued the study. Response can be partial or complete (as previously defined), whichever status is recorded first.

    Time frame: Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  7. Time to Progression

    Progression is defined as the first evaluation that shows progression (either by RECIST or WHO criteria): Progressive Disease according to RECIST response criteria: \>=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease. Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.

    Time frame: Time of treatment until progression, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).

  8. Duration of Overall Survival

    Patients were followed with regards to survival even after they left the trial (ie after End of Treatment visit). Deaths that occurred after patient participation ended were collected all the way through to the overall end of the trial which took place on Oct 31, 2009. These deaths were used to calculate overall survival.

    Time frame: Time of treatment until death, up to the time that all participants ended treatment

  9. Number of Days the Patients Were Hospitalized for Cancer-related Symptoms or Toxicity of Treatment

    The cumulative sum of hospitalization days during the study, per patient. Some patients had multiple hospitalizations.

    Time frame: Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment).

07

Results

Posted May 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneCaelyx
Started25
Completed25
Not completed0

Outcome measures

PrimaryTime to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death).

Treatment failure was defined as progression of disease (according to the RECIST or WHO criteria) or unacceptable toxicity leading to discontinuation of treatment or death. Progressive Disease according to RECIST response criteria: \>=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease. Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.

Time frame:
Time of treatment until progression of disease or unacceptable toxicity leading to discontinuation of treatment or death, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Median · Months
Time to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death).
MonthsCaelyx
Time to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death).5.52 (3.67 to 8.52)
SecondaryNumber of Patients With Stable Disease (SD) as Best Response

Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST response criteria for SD required steady state of response of at least 9 weeks duration. There may be no appearance of new lesions. WHO response criteria for SD required no significant change for at least 8 weeks.

Time frame:
Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Number · participants
Number of Patients With Stable Disease (SD) as Best Response
participantsCaelyx
Patients followed by RECIST only (n=10)5
Patients followed by WHO only (n=4)4
Patients followed by RECIST & WHO (n=8)4
SecondaryNumber of Patients With Partial Response (PR) as Best Response

Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST PR criteria required \>=30% decrease in certain target lesions \& no increase in size of non-target lesions or appearance of new lesions WHO PR criteria required partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for \>=4 wks

Time frame:
Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Number · participants
Number of Patients With Partial Response (PR) as Best Response
participantsCaelyx
Patients followed by RECIST only (n=10)1
Patients followed by WHO only (n=4)0
Patients followed by RECIST & WHO (n=8)2
SecondaryNumber of Patients With Progressive Disease (PD) as Best Response

Response was calculated according to RECIST criteria except for bone metastasis where WHO criteria was used. For patients with skeletal disease only, WHO criteria was used. For patients with measurable disease according to RECIST as well as bone metastasis, both RECIST \& WHO were used. RECIST PD criteria required \>=20% increase in certain target lesions OR progression of non-target lesions, or appearance of new lesions WHO PD criteria required increase in size of existing lesions or appearance of new lesions.

Time frame:
Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Number · participants
Number of Patients With Progressive Disease (PD) as Best Response
participantsCaelyx
Patients followed by RECIST only (n=10)4
Patients followed by WHO only (n=4)0
Patients followed by RECIST & WHO (n=8)2
SecondaryNumber of Patients Requiring Dose Reduction

The protocol contains instructions to reduce the Caelyx dose according to specific schedules, in cases necessary due to reasons such as hematological toxicity, non-hematological toxicity, cardiotoxicity, or other toxic side-effects of treatment reducing quality of life etc.

Time frame:
Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment).
Reported as:
Number · participants
Number of Patients Requiring Dose Reduction
participantsCaelyx
Due to weight change6
Due to toxicity/adverse event4
SecondaryTime to Response

Response can be partial (\>=30% decrease in the sum of Longest Diameter of target lesions, determined by two observations not less than 4 weeks apart; no unequivocal increase in the size of non-target lesions or the appearance of new lesions may occur) or complete (disappearance of all clinical evidence of tumor determined by 2 observations not less than 4 weeks apart), whichever status is recorded first.

Time frame:
Time of treatment until response, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Median · Weeks
Time to Response
WeeksCaelyx
Patient 112.2 (12.2 to 12.2)
Patient 211.4 (11.4 to 11.4)
Patient 312.0 (12.0 to 12.0)
SecondaryDuration of Response

Duration of response is defined as the time span from the first evaluation that shows response until the first evaluation that shows progression. Where patients did not show progress, duration of response was measured from the first evaluation that showed response until they discontinued the study. Response can be partial or complete (as previously defined), whichever status is recorded first.

Time frame:
Time of treatment until treatment discontinuation, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Median · weeks
Duration of Response
weeksCaelyx
Patient 111.8 (11.8 to 11.8)
Patient 248.6 (48.6 to 48.6)
Patient 317.8 (17.8 to 17.8)
SecondaryTime to Progression

Progression is defined as the first evaluation that shows progression (either by RECIST or WHO criteria): Progressive Disease according to RECIST response criteria: \>=20% increase in the sum of the Longest Diameter of target lesions or unequivocal progression of non-target lesions. Appearance of new lesions will also constitute progressive disease. Progressive Disease according to WHO response criteria: Increase in size of existing lesions or appearance of new lesions.

Time frame:
Time of treatment until progression, assessed every 12th week until end of treatment (study planned to continue until all participants ended treatment).
Reported as:
Median · months
Time to Progression
monthsCaelyx
Time to Progression5.69 (3.74 to 13.8)
SecondaryDuration of Overall Survival

Patients were followed with regards to survival even after they left the trial (ie after End of Treatment visit). Deaths that occurred after patient participation ended were collected all the way through to the overall end of the trial which took place on Oct 31, 2009. These deaths were used to calculate overall survival.

Time frame:
Time of treatment until death, up to the time that all participants ended treatment
Reported as:
Median · months
Duration of Overall Survival
monthsCaelyx
Duration of Overall Survival20.6 (6.58 to 25.6)
SecondaryNumber of Days the Patients Were Hospitalized for Cancer-related Symptoms or Toxicity of Treatment

The cumulative sum of hospitalization days during the study, per patient. Some patients had multiple hospitalizations.

Time frame:
Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment).
Reported as:
Number · days
Number of Days the Patients Were Hospitalized for Cancer-related Symptoms or Toxicity of Treatment
daysCaelyx
Patient 11
Patient 21
Patient 36
Patient 44
Patient 55
Patient 671
Patient 716
Patient 81
Patient 91
Patient 103
Patient 1133
Patient 1220

Adverse events

Collected over Time of treatment until treatment discontinuation (study planned to continue until all participants ended treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caelyx—9/25 (36%)25/25 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCaelyx
PYREXIAGeneral disorders2/25
URINARY TRACT INFECTIONInfections and infestations2/25
MYOCARDIAL INFARCTIONCardiac disorders1/25
ABDOMINAL PAINGastrointestinal disorders1/25
DYSPEPSIAGastrointestinal disorders1/25
VOMITINGGastrointestinal disorders1/25
CENTRAL LINE INFECTIONInfections and infestations1/25
CLOSTRIDIAL INFECTIONInfections and infestations1/25
CYSTITISInfections and infestations1/25
PNEUMONIAInfections and infestations1/25
Most frequent other events
Showing 10 of 34
Most frequent other events
EventCaelyx
FATIGUEGeneral disorders17/25
NAUSEAGastrointestinal disorders16/25
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders13/25
DECREASED APPETITEMetabolism and nutrition disorders9/25
VOMITINGGastrointestinal disorders7/25
CONSTIPATIONGastrointestinal disorders6/25
DIARRHOEAGastrointestinal disorders6/25
STOMATITISGastrointestinal disorders6/25
PYREXIAGeneral disorders6/25
BACK PAINMusculoskeletal and connective tissue disorders6/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Caelyx
<=18 years0
Between 18 and 65 years0
>=65 years25
Age, Continuous
Age, Continuous(years)Caelyx
Mean72.3 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Caelyx
Female25
Male0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Green H, Stal O, Bachmeier K, Backlund LM, Carlsson L, Hansen J, Lagerlund M, Norberg B, Franzen A, Aleskog A, Malmstrom A. Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett. 2011 Dec 27;313(2):145-53. doi: 10.1016/j.canlet.2011.07.017. Epub 2011 Aug 31. PubMed 22056077 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2007 to primary completion in Oct 2009, 32 months.

Results were first posted in May 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2008
First posted
Jan 30, 2008
StartActual
Feb 7, 2007
Primary completionActual
Oct 16, 2009
CompletionActual
Oct 16, 2009
Results first posted
May 2, 2011
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00604968
Responsible party
Sponsor
First posted
Jan 30, 2008
Start date
Feb 7, 2007
Primary completion
Oct 16, 2009
Completion
Oct 16, 2009
Results posted
May 2, 2011
Last update
Jun 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion